NCT07123922Enrolling by invitation
Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patients.
Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patients; A Randomized Double-Blind Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 14 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if Silymarin works to reduce oxidative stress, improve pulmoary function and quality of life in stable COPD patients. It will also learn about the safety of drug Silymarin. The main questions it aims to answer are: Does drug Silymarin reduce oxidative stress, improve pulmonary function and quality of life in stable COPD patients? What medical problems do participants have when taking drug Silymarin? Researchers will compare Silymarin to a placebo (a look-alike substance that contains no drug) to see if Silymarin works to treat COPD. Participants will: Take Silymarin or a placebo thrice daily every day for 3 months. Baseline and 3 months after plasma Malondealdehyde, erythrocyte Glutathione , FEV1, SGRQ-C score will be monitored.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 18 Jun 2025
- Start date
- 20 Jun 2025
- Primary completion date
- 15 Nov 2025
- Lead sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Diseases
- COPD
- NCT number
- NCT07123922
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 20 Jun 2025 to the primary completion date, 15 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • COPD exacerbation
- Presence of other respiratory diseases like asthma, bronchiectasis, interstitial lung disease, tuberculosis or lung cancer
- Diagnosed case of diabetes mellitus, liver disease, heart disease, kidney stones and disease, hyperparathyroidism, other malignancies
- Use of other antioxidant drugs like Vitamin C, E, N acetylcysteine within last 1 months
- Known hypersensitivity to Silymarin
Who the study is looking for
- Diagnosed case of COPD according to GOLD guideline (post bronchodilator FEV1/FVC \< 0.7).
- Age 40-80 years
- No exacerbation or hospitalization due to exacerbation in the last 1 month.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BSMMU Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.